MaxCyte ( (MXCT) ) has shared an update.
MaxCyte, Inc. announced the issuance of 354,885 shares of common stock as part of its block admission facility, following the exercise of share options and vesting of restricted stock units. This brings the total issued stock capital to 106,313,718 shares, which shareholders can use to calculate their interest in the company. This move reflects MaxCyte’s ongoing commitment to expanding its capital base, potentially enhancing its market position and providing additional resources to support its growth in the cell therapy sector.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell engineering industry, focusing on platform technologies that advance the discovery, development, and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications. The company offers the ExPERT™ platform, which includes instruments, processing assemblies, and software protocols, all supported by a robust intellectual property portfolio. MaxCyte aims to support the high-growth cell therapy market from discovery through commercialization.
YTD Price Performance: -35.49%
Average Trading Volume: 40,863
Technical Sentiment Signal: Buy
Current Market Cap: £224M
Learn more about MXCT stock on TipRanks’ Stock Analysis page.